| Literature DB >> 31288755 |
Yinjuan Guo1, Yu Ding2, Li Liu3, Xiaofei Shen3, Zhihao Hao3, Jingjing Duan3, Ye Jin3, Zengqiang Chen3, Fangyou Yu4.
Abstract
BACKGROUND: Staphylococcus epidermidis has emerged as an often encountered pathogen responsible for hospital-acquired infections. The aim of present study is to investigate the microbiological characteristic of S. epidermidis isolates isolated from sterile specimens and skin in a Chinese tertiary hospital.Entities:
Keywords: MLST; Resistance; Staphylococcus epidermidis; Virulence-genes
Year: 2019 PMID: 31288755 PMCID: PMC6617921 DOI: 10.1186/s12866-019-1523-6
Source DB: PubMed Journal: BMC Microbiol ISSN: 1471-2180 Impact factor: 3.605
Antimicrobial resistance profiles and carriage of virulence genes among S. epidermidis clinical and colonized isolates
| Clinical isolates ( | Colonized isolates ( | ||||
|---|---|---|---|---|---|
| No. | % | No. | % | ||
| Antimicrobials | |||||
| penicillin | 213 | 95.52 | 87 | 82.08 | 0.000 |
| tetracycline | 76 | 34.08 | 19 | 17.92 | 0.004 |
| ciprofloxacin | 66 | 29.60 | 37 | 34.91 | 0.000 |
| chloramphenicol | 78 | 34.98 | 10 | 9.43 | 0.000 |
| gentamicin | 72 | 32.29 | 21 | 19.81 | 0.000 |
| clindamycin | 110 | 49.33 | 36 | 33.96 | 0.000 |
| erythromycin | 184 | 82.51 | 66 | 62.26 | 0.000 |
| Trimethoprim/sulfamethoxazole | 99 | 44.39 | 27 | 25.47 | 0.000 |
| linezolid | 0 | 0.00 | 1 | 0.94 | 0.684 |
| vancomycin | 0 | 0.00 | 0 | 0.00 | NAa |
| Biofilm formation | 21 | 9.42 | 19 | 17.92 | |
| Virulence genes | |||||
| | 46 | 20.63 | 24 | 22.64 | 0.202 |
| | 148 | 66.37 | 61 | 57.55 | 0.022 |
| | 39 | 17.49 | 4 | 3.77 | 0.000 |
| | 112 | 52.02 | 37 | 34.91 | 0.000 |
| | 97 | 43.50 | 2 | 1.89 | 0.000 |
| | 102 | 22.32 | 0 | 0.00 | 0.000 |
| | 443 | 96.94 | 13 | 12.26 | 0.000 |
| | 168 | 36.76 | 7 | 6.60 | 0.000 |
| Resistance genes | |||||
| | 41 | 18.38 | 11 | 10.38 | 0.065 |
| | 100 | 44.84 | 57 | 53.77 | 0.058 |
a NA not analyzed
Sequence types (ST) distribution among S. epidermidis clinical isolates and colonized isolates
| MLST | CC | Clinical isolates( | Colonized isolates( | ||
|---|---|---|---|---|---|
| No. | % | No. | % | ||
| ST2 | 2 | 28 | 12.56% | 1 | 0.94% |
| ST5 | 2 | 1 | 0.45% | 0 | 0.00% |
| ST10 | 2 | 2 | 0.90% | 0 | 0.00% |
| ST14 | 2 | 7 | 3.14% | 5 | 4.72% |
| ST16 | 2 | 2 | 0.90% | 0 | 0.00% |
| ST20 | 2 | 8 | 3.59% | 14 | 13.21% |
| ST21 | 2 | 3 | 1.35% | 0 | 0.00% |
| ST57 | 2 | 4 | 1.79% | 2 | 1.89% |
| ST59 | 2 | 12 | 5.38% | 3 | 2.83% |
| ST89 | 2 | 3 | 1.35% | 0 | 0.00% |
| ST125 | 2 | 6 | 2.69% | 1 | 0.94% |
| ST130 | 2 | 16 | 7.17% | 19 | 17.92% |
| ST210 | 2 | 9 | 4.04% | 1 | 0.94% |
| ST226 | Singletons | 4 | 1.79% | 0 | 0.00% |
| ST227 | 227 | 5 | 2.24% | 1 | 0.94% |
| ST234 | 2 | 3 | 1.35% | 1 | 0.94% |
| ST235 | 2 | 6 | 2.69% | 0 | 0.00% |
| ST248 | 2 | 1 | 0.45% | 1 | 0.94% |
| ST262 | Singletons | 4 | 1.79% | 0 | 0.00% |
| ST263 | 365 | 5 | 2.24% | 1 | 0.94% |
| ST466 | 2 | 20 | 8.97% | 16 | 15.09% |
| Non typing | 13 | 5.83% | 12 | 11.32% | |
| Other | 61 | 27.35% | 28 | 26.42% | |
| Total | 223 | 100.00% | 106 | 100.00% | |
CC clonal complex
Fig. 1eBURST analysis of S.epidermidis using all STs available in the MLST database. ST2 was the founder of S. epidermidis in MLST database. ST5, the single locus variant (SLV) of ST2, was the founder of clinical isolates, while ST85, also the SLV of ST2, was the founder of colonized isolates
Fig. 2eBURST analysis of S. epidermidis clinical isolates (a) and colonized isolates (b). The eBURST algorithm clustered all of the 60 STs isolated of clinical isolates into clonal complex 2 (CC2) (166/223; 74.40%), 7 minor CCs (CC365, CC193, CC227, CC171, CC33, CC326, and CC66, 16/223, 7.17%), and 29 singletons. Among the 106 colonized isolates, 5 CCs were identified, including CC2 (77/106; 72.64%), CC365 (4 isolates), CC193 (1 isolates), CC227 (1 isolates) and CC66 (1 isolates)
The antimicrobial resistance rates, positive rates of virulence genes and of resistance genes among S.epidermidis clinical isolates with major ST types (%)
| ST466 ( | ST2 ( | ST130 ( | ST20 ( | ST59 ( | |
|---|---|---|---|---|---|
| Antimicrobials | |||||
| penicillin | 95(19) | 96.43(27) | 100.00(16) | 100.00(8) | 91(11) |
| tetracycline | 50.00(10) | 10.71(3) | 25.00(4) | 50.00(4) | 33.33(4) |
| ciprofloxacin | 15.00(3) | 82.14(23) | 25.00(4) | 50.00(4) | 33.33(4) |
| chloramphenicol | 30.00(6) | 25.00(7) | 12.50(2) | 12.50(1) | 0.00(0) |
| gentamicin | 20.00(4) | 82.14(23) | 25.00(4) | 0.00(0) | 33.33(4) |
| clindamycin | 30.00(6) | 67.86(19) | 50.00(8) | 25.00(2) | 41.67(5) |
| erythromycin | 80.00(16) | 82.14(23) | 68.75(11) | 87.50(7) | 83.33(10) |
| SXTa | 60.00(12) | 71.43(20) | 100(16) | 0.00(0) | 41.67(5) |
| linezolid | 0.00(0) | 0.00(0) | 0.00(0) | 0.00(0) | 0.00(0) |
| vacomycin | 0.00(0) | 0.00(0) | 0.00(0) | 0.00(0) | 0.00(0) |
| Biofilm formation | 5.00(1) | 10.71(3) | 0.00(0) | 75.00(6) | 0.00(0) |
| Virulence genes | |||||
| | 0.00(0) | 85.71(24) | 0.00(0) | 62.50(5) | 0.00(0) |
| | 90.00(18) | 96.43(27) | 50.00(8) | 50.00(8) | 91.67(11) |
| | 0.00(0) | 96.43(27) | 0.00(0) | 0.00(0) | 25.00(3) |
| ACME- | 65.00(13) | 39.29(11) | 87.50(14) | 25.00(2) | 41.67(5) |
| | 15.00(3) | 82.14(23) | 43.75(7) | 25.00(2) | 33.33(4) |
| | 30.00(6) | 10.71(3) | 0.00(0) | 0.00(0) | 50.00(6) |
| | 100.00(20) | 92.86(26) | 100.00(16) | 100.00(8) | 100.00(12) |
| | 100.00(20) | 96.43(27) | 100.00(16) | 100.00(8) | 100.00(12) |
| | 25.00(5) | 67.86(19) | 12.50(2) | 62.50(5) | 33.33(4) |
| Resistance genes | |||||
| | 0.00(0) | 39.29(11) | 12.50(2) | 12.50(1) | 8.33(1) |
| | 65.00(13) | 67.86(19) | 56.25(9) | 62.50(5) | 58.33(7) |
a SXT trimethoprim/sulfamethoxazole
Fig. 3The competence of ST466 clone with S. aureus (SA75) were significantly stronger than ST2 and ST130 clones (Fig. 3) (P < 0.05). Although the competence of ST466 clone with S. aureus was higher than ST20 and ST59 clones, there were no differences among them, especially ST59 with similar competence relative to ST466